To establish a prospective, longitudinal cohort of participants who can provide blood, tissue (including kidney histology), urine samples to establish a core biobank for kidney disease research. Results from this biobank will be matched to clinical outcomes to facilitate the discovery (and/or validation) of novel prognostic, predictive or diagnostic biomarkers important for kidney disease.
Hypothesis: Genetic ancestry influences the enrichment of certain polymorphisms, which may have important protective or adverse effects on important kidney related outcomes, including developing chronic kidney disease, progression to kidney failure, and/or poor long-term outcomes following kidney transplantation. Aims: To establish a prospective, longitudinal cohort of participants who can provide blood, tissue (including kidney histology), urine samples to establish a core biobank for kidney disease research. Results from this biobank will be matched to clinical outcomes to facilitate the discovery (and/or validation) of novel prognostic, predictive or diagnostic biomarkers important for kidney disease. Data from this cohort will be used to determine if genomic factors independently influence: 1. The susceptibility to developing acute kidney injury (AKI) and the severity of AKI. 2. The development of chronic kidney disease (CKD), and the complications of CKD 3. The progression to kidney failure (needing dialysis or transplant) and complications of kidney failure? 4. The risk of treatment failure (or resistance) to standard medical therapy for any of the above (1-4)?
Study Type
OBSERVATIONAL
Enrollment
500
Royal Prince Alfred Hospital
Sydney, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Westmead Institute for Medical Research
Westmead, New South Wales, Australia
Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia
Development of CKD
Group 1 develops eGFR ≤ 60ml/min/1.73m2 (or biopsy proven kidney disease) ≥ 3-months, or albuminuria or proteinuria (UACR \> 3mg/mmol or UPCR \> 10mg/mmol) ≥ 3-months
Time frame: 20 years
Progression of CKD
For group 2, defined by eGFR decline ≥ 30% from baseline for ≥ 3 months, or eGFR decline to below 15ml/min/1.73m2 if baseline eGFR \> 30ml/min/1.73m2, or the need for renal replacement therapy
Time frame: 20 years
Removal from dialysis
For group 3 - either death (survival time on dialysis) if they do not receive a kidney transplant during the study, or if they receive a kidney transplant
Time frame: 20 years
Death
death from any cause
Time frame: 20 years
Hospital Admissions
Hospital or emergency department visits for any reason
Time frame: 20 years
estimated glomerular filtration rate slope
change in eGFR over time
Time frame: 10 and 20 year time points
Cardiovascular event or major risk factors
(MACE): non-fatal stroke, non-fatal myocardial infarction, cardiovascular death. Major risk factors: diabetes mellitus, dyslipidaemia, obesity, hypertension
Time frame: 20 years
Major infectious events
bacterial, fungal or viral infection which necessitates hospital admission or medical attention
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 20 years
Malignancy
any cancer diagnosis following enrolment
Time frame: 20 years
acute kidney episodes
acute kidney episodes (defined by KDIGO criteria), registry code or clinician assignment for group 1 or 2
Time frame: 20 years
Dialysis dose
time on dialysis (hours/days) and dialysis prescription (if available)
Time frame: 10 years